Severe exacerbations requiring hospitalisation over the study period · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in predose FEV1 (mL) compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
FEV1 % predicted · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
MIP ‐ undernourished cm H2O · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
HRQoL ‐ SGRQ ‐ subgrouped by domain ‐ total · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
HRQoL ‐ SGRQ subgrouped by domain ‐ activity · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
HRQoL ‐ SGRQ subgrouped by domain ‐ impact · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
HRQoL ‐ SGRQ subgrouped by domain ‐ symptoms · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Weight (change from baseline ‐ undernourished) kg · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Weight (undernourished) kg · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Fat‐free mass/fat‐free mass index (change from baseline; undernourished participants) kg/m2 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Fat mass/fat mass index (change from baseline; undernourished participants) kg/m2 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
MAMC ‐ change from baseline · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
Fat‐free mass index (undernourished patients) kg/m2 · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
FEV1 litres and % predicted · stable chronic obstructive pulmonary disease
1 finding from 1 review
Intervention not reported
FEV1 litres · stable chronic obstructive pulmonary disease
1 finding from 1 review